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1. Introduction
The outstanding progress in advanced molecular technologies has provided a tremendous
amount of data that has altered the way in which we classify and categorize pediatric brain
tumors. From the initial identification of chromosomal aberrations by karyotyping and com‐
parative genomic hybridization, we have rapidly moved to expression array studies and to
integrative genomic approaches which allowed the stratification of several pediatric brain
tumors into molecular subgroups. These data have not only increased our understanding of
the molecular pathogenesis of pediatric brain tumors, but have also identified prognostic
markers and opened new avenues for targeted therapies.
One of the most important discoveries in pediatric astrocytomas was the duplication and the
mutation of the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) gene, found in pi‐
locytic astrocytomas and malignant astrocytomas, respectively. Clinical trials using BRAF
signaling pathway inhibitors are currently ongoing.
Until recently, the biology of diffuse intrinsic pontine glioma (DIPG) was poorly under‐
stood. Overexpression of epidermal growth factor receptor (EGFR) and platelet-derived
growth factor receptor alpha (PDGFRα) amplification have now been reported in multiple
studies in DIPG and clinical trials with the respective inhibitors (nimotuzumab for EGFR
and dasatinib for PDGFRα), alone or in combination with other drugs, are in progress.
Integrated genomics has shown that medulloblastoma, the most common malignant pedia‐
tric brain tumor, comprises four distinct molecular and clinical variants. The stratification of
patients into the Wnt subgroup, the sonic hedgehog (SHH) subgroup, Group 3 and Group 4
may lead to the identification of those patients that will most likely benefit from targeted
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therapies, like SMO inhibitors. Moreover, this molecular classification may help identify pa‐
tients predicted to have a poor prognosis, who may benefit from intensified therapies, and
patients with a favorable prognosis that potentially benefit from reduced radiation and che‐
motherapy regimens. It is already known from four independent studies that the Wnt sub‐
group patients have a very good prognosis while patients in Group 3 have a high incidence
of metastasis and a dismal prognosis.
The transcriptional profiling of two large independent cohorts of posterior fossa ependymo‐
mas also identified two groups with distinct molecular and clinical features. Group A epen‐
dymomas have a balanced genome, occur in younger patients and tumors are located
laterally. These patients have a worse clinical outcome and higher incidence of metastasis
and recurrence. In contrast, Group B ependymomas occur in the midline and have a better
prognosis. Since ependymomas are usually refractory to current chemotherapeutic agents,
these discoveries may shed some light into the pathways involved in tumor initiation and
progression and also identify new targets for therapy.
We are now facing the next-generation (Next-Gen) sequencing era which will provide further
insights into the dysregulated signaling pathways in each tumor type. The identification of
driver mutations will allow a better understanding of tumorigenesis and lead to the develop‐
ment of more accurate preclinical models. Moreover, the profiling of transcriptomes, genetic
and epigenetic events of large cohorts of tumors will eventually shed some light into the cells of
origin of specific subgroups and also the important driver events for tumor initiation, mainte‐
nance and progression. On the clinical side, this knowledge will allow the stratification of pa‐
tients into appropriate risk groups and the tailoring of treatments according to each tumor’s
genomic landscape. In this chapter we describe the latest advances in molecular genomics of
the most common pediatric brain tumors as well as its prognostic significance and relevance to
the clinic. We also highlight the most recent clinical trials using molecular targeted therapies
and discuss further possible avenues in the treatment of pediatric brain cancer.
2. Astrocytomas
Astrocytomas are a common brain tumor in children. According to the 2007 classification of the
World Health Organization (WHO) they can be classified into four grades (WHO grade I-IV),
which reflect their biological and clinical behavior. Pilocytic astrocytomas (WHO grade I) rep‐
resent the most frequent brain tumor in the pediatric population and have excellent survival
rates over 95% [1]. On the other hand, glioblastomas (WHO grade IV) are aggressive tumors,
often non-responsive to treatments and with survival rates ranging from 10% to 30% [1]. We
will focus on the molecular biology of these two types of pediatric astrocytomas.
2.1. Pilocytic astrocytoma
The first-line treatment for pilocytic astrocytoma (PA) is surgical resection. Although most
children with these tumors survive for a long time, some will experience tumor recurrence,
especially if the tumor resection is incomplete. Recurrent and progressive tumors are treated
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with radiation and/or chemotherapy but, until recently, the mechanisms of recurrence and
malignant transformation were poorly understood.
Early studies on chromosomal aberrations in PAs showed normal karyotypes in most cas‐
es. Trisomy of chromosomes 5 and 7 and 7q gains were some of the few cytogenetic ab‐
normalities  found  [2].  Using  an  array-based  comparative  genomic  hybridization  (array-
CGH),  Pfister  et  al.  studied  a  large  series  of  pediatric  low-grade  astrocytomas  and
uncovered mechanisms of mitogen-activated protein kinase (MAPK) activation in these tu‐
mors. The authors identified a tandem duplication of the BRAF gene locus (7q34) in more
than 50% of the PAs and, in a smaller percentage (~6%) of tumors, a BRAF activating mu‐
tation V600E (a valine to glutamate change at hotspot codon 600) [3]. Later, it was demon‐
strated that the constitutive activation of BRAF was due to a fusion between a novel gene
(KIAA1549) and the BRAF oncogene and also that this fusion was related to a better clini‐
cal outcome in incompletely resected low-grade astrocytomas [4]. Other, less frequent, re‐
ported gene fusions in PAs include the fusion of BRAF  with the FAM131B  gene and the
fusion between a Raf kinase family member (RAF1) and SLIT-ROBO Rho GTPase-activat‐
ing protein 3 (SRGAP3) gene [5]. The combined analysis of BRAF and isocitrate dehydro‐
genase 1 (IDH1) was shown to be both sensitive and specific to separate PAs from diffuse
astrocytomas (WHO grade II). PAs contained the KIAA1549:BRAF  fusion in 70% of cases
but no IDH2  or IDH2  mutations while diffuse astrocytomas exhibited 76% of cases with
IDH1  mutations but no BRAF  fusion [6]. There is also an interesting correlation between
tumor location and the type of MAPK alteration. Posterior fossa tumors usually have in‐
creased  incidence  of  KIAA1549:BRAF  fusion  while  supratentorial  tumors  have  high  fre‐
quency  of  BRAFV600E  mutation.  Approximately  80-90%  of  PA  cases  reported  in  the
literature have at least one alteration in the MAPK pathway. Interestingly, all the altera‐
tions described in the MAPK pathway seem to be mutually exclusive suggesting that  a
single hit may be sufficient to induce transformation [5].
With the discovery of constitutive activation of MAPK pathway and BRAF alterations in
most PAs, there has been an increasing interest in using these targets for novel therapeutic
approaches. A number of phase I and phase II clinical trials are ongoing to test small mole‐
cule inhibitors of MAPK and related pathways (Table 1).
Drug
Clinical Trial Reference(http://clinicaltrials.gov)Group Name
MEK inhibitor AZD6244 Phase I NCT01386450, NCT01089101
RAF inhibitor
(multikinase inhibitor) Sorafenib Phase II NCT01338857 (suspended)
mTOR inhibitor Everolimus Phase II NCT01158651, NCT00782626
Table 1. Pediatric clinical trials for pilocytic astrocytomas using targeted therapies
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2.2. Glioblastoma multiforme
Glioblastoma multiforme (GBM) is the most common brain tumor in adults and is less fre‐
quent in the pediatric population. Despite improvements in neurosurgery and neuro-oncol‐
ogy, children diagnosed with GBM still have a dismal outcome with low survival rates even
with aggressive therapeutic regimens. Although the histology of pediatric and adult GBMs
appears identical, the molecular biology of these tumors is different. Therefore, the develop‐
ment of effective therapies for GBM in children should probably not rely on advances made
in adult tumors.
Mutations in phosphatase and tensin homolog (PTEN) and amplifications of EGFR are com‐
mon in adult malignant gliomas but less frequent in the pediatric setting. However, when
compared to pediatric low-grade gliomas, pediatric GBMs have a significant higher expres‐
sion of EGFR, although with no reported mutations and few deletions (~17%) in EGFRvIII
[7]. While in adult GBMs the activation of the AKT pathway is a result of PTEN mutations,
in pediatric tumors these are infrequent, although overexpression of AKT and its association
with poor survival has been reported [8,9]. In a study with a large cohort of pediatric high-
grade gliomas (HGGs) (37 GBMs out of 63 tumor samples), Bax et al. identified PDGFRα
amplification and cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) deletion as the most
frequent focal events. Interestingly, the patients with high-grade tumors and a stable ge‐
nomic profile had a better survival, independent of the histological grade or type [10]. Sever‐
al studies showed that IDH1 mutations, common in adult secondary GBM (98%), are rare in
pediatric GBM [7]. TP53 (tumor protein 53) mutations were reported in pediatric high-grade
tumors with an increased frequency in older children (40%) when compared to those less
than 3 years (12%) [11]. Overexpression of p53, but not TP53 mutations, was also associated
with a significant reduction in the 5 year progression-free survival [12]. A recent study used
high resolution single nucleotide polymorphism (SNP) arrays to identify novel chromoso‐
mal alterations in pediatric GBM, including amplifications of 7q21-22 and 1q43-44 and loss
of heterozygosity (LOH) in15q15.1-15q23 and 17p13-17p11.2. Genes involved in cell-cycle
regulation and cell death pathways were the predominant targets of LOHs [13].
It has been shown that overexpression of O6-methylguanine-DNA methyltransferase
(MGMT) is rare in HGGs but it has also been reported that it is associated with a poor over‐
all survival in children. The MGMT gene encodes a DNA-repair enzyme that can reduce the
efficacy of alkylating agents. When the MGMT gene is silenced by promoter methylation,
DNA repair in tumor tissue is compromised and patients have a better survival [7].
Finaly, a very recent study uncovered an interesting interplay between genetic and epige‐
netic events in pediatric GBM. The authors performed whole-exome sequencing in 48 pedia‐
tric GBMs and identified 44% of tumors harbouring somatic mutations in genes involved in
the chromatin remodeling pathway, including the histone H3 gene (H3F3A), the α-thalassae‐
mia/mental retardation syndrome X-linked (ATRX) gene and the death-domain associated
protein (DAXX) gene [14]. Interestingly, the H3F3A mutations were found to be specific of
GBMs and more prevalent in the pediatric population. Moreover, 54% of all cases and 86%
of patients with H3F3A and/or ATRX mutations, also showed TP53 somatic mutations [14].
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The novel targeted therapies that are currently under clinical investigation for high-grade
gliomas, including GBM, are reviewed in reference [15].
3. Diffuse intrinsic pontine glioma
Despite decades of clinical research, the prognosis of diffuse intrinsic pontine glioma (DIPG)
remains dismal with more than 90% of affected children dying within two years of diagnosis
[16]. The only known effective treatment is radiation therapy although in most patients it
has a transient effect. Different combinations of chemotherapy, radiation and radiosensitiz‐
ers were attempted but failed to improve long-term survival [17]. The indication for biopsy
in DIPG has been reserved for atypical tumors (prominent enhancement in magnetic resso‐
nance imaging (MRI), low T2/FLAIR signal and/or high signal on diffuse imaging). Howev‐
er, the recognition that it is crucial to understand the biology of DIPG in order to design
more rational drug treatments, led to a plea for routine biopsies in these patients. Some
groups are already performing regular image-guided stereotactic biopsies in patients with
DIPGs [18,19] and, furthermore, biopsies have been included in a clinical trial to decide
which patients with DIPG would benefit from targeted therapy with erlotinib, an EGFR in‐
hibitor [20]. Autopsies became another important source of DIPG tissue collection. Recent
studies showed that up to 50% of parents agree with the autopsy and, if done within a short
period of time after death, it is possible to obtain good quality DNA and RNA and even cul‐
ture primary DIPG cell lines [21-23].
The paradigm shift to obtain tissue from patients with DIPG not only increased our knowl‐
edge in the molecular biology of the disease but also raised important clinical considera‐
tions. Paugh et al. described differences at the copy number and expression level in both
adult and pediatric HGGs, including DIPGs. They showed that gain of chromosome 1q and
PDGFRα amplification were frequent in children while chromosome 7 gain, 10q loss and
EGFR amplification were characteristic of adult HGGs [24]. The identification of these two
distinct biological entities has important clinical implications since pediatric clinical trials
over the past decades have been designed with drugs known to have some activity in adult
HGGs. It is now clear that DIPG has to be considered and treated as a separate disease. The
same group compared the copy number alterations (CNAs) in DIPGs and nonbrainstem pe‐
diatric glioblastomas concluding that they are also genomically distinct. They identified re‐
ceptor tyrosine kinase and retinoblastoma protein (RB) amplifications in 47% and 30% of
DIPG cases, respectively, and found high frequency of focal amplifications of PDGFRα, MET
and insuline-like growth factor receptor 1 (IGF1R) [25]. Furthermore, Zarghooni et al., using
SNP arrays, showed that DIPGs have distinct CNAs from pediatric supratentorial high-
grade astrocytomas, with gains in PDGFRα and poly (ADP-ribose) polymerase-1 (PARP-1)
amongst the most frequent [26]. Another group showed other differences between these tu‐
mors including frequent losses of 17p and 14q in DIPGs [27]. A very recent study used DNA
from tumor tissue obtained at diagnosis by steriotactic biopsies and identified oncogenic
mutations in TP53 (40%), PI3KCA (15%) and ATM/MPL (5%). In fact, PI3KCA represents the
first mutated oncogene described in DIPG [28].
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Another level of gene expression regulation in DIPG occurs through epigenetic mechanisms,
including histone modifications. Very recent sudies used whole-genome sequencing in large
cohorts of DIPGs to identify somatic mutations in the H3F3A gene. Khuong-Quang et al. re‐
ported mutations in H3.3 that resulted in the substitution of lysine by methionine at amino
acid 27 (K27M-H3.3) in 71% of cases and the presence of these mutations were associated
with a worse survival independent of patient age and histological grade [29]. Furthermore,
gains or amplifications in PDGFRα and MYC/PVT1 were exclusively seen in K27M-H3.3 mu‐
tants. The authors also described TP53 mutations in 77% and ATRX mutations in 9% of
DIPGs [29]. Interestingly, both the mutated and wild-type H3.3 subgroups showed high fre‐
quency of TP53 mutation. In another study, Wu et al. identified mutations in H3F3A (enco‐
des histone H3.3) and HIST1H3B (encodes histone H3.1) in 78% of DIPGs and 22% of
nonbrainstem pediatric glioblastomas [30]. The different H3 mutations were mutually exclu‐
sive and seemed to be a feature of pediatric HGGs.
The discoveries from the molecular biology of DIPGs identified several drugable targets al‐
lowing the development of molecular target-based trials that are summarized in Table 2.
Some of these trials have shown a subset of patients with survival longer than expected and,
therefore, several other trials are ongoing, some of them including combined therapies
[17,31].
Finally, DIPG treatment involves another challenge which is drug distribution. Probably
due to an intact blood-brain barrier, penetration of drugs in the pons seems to be poor, a fact
demonstrated by the lack of gadolinium enhancement in the MRI in most DIPGs. Therefore,
it is crucial to improve drug delivery either by disrupting the blood-brain barrier (e.g. fo‐
cused ultrasound or drugs that increase permeability such as manitol), by local delivery (tu‐
mor injection or convection enhanced delivery) or even nanoparticles [17]. These techniques
may promote high drug concentrations in the pons, including agents that normally don’t
cross the blood-brain barrier.
Drug Clinical Trial 1 year Overall Survival (OS) Reference
Imatinib Phase I 45.5% 2007 [32]
Tipifarnib Phase I 36.4% 2008 [33]
Gefitinib Phase I 48% 2010 [34]
Vandetanib Phase I 37% 2010 [35]
Erlotinib Phase I 50% 2011 [20]
Gefitinib Phase II 56% 2011 [36]
Nimotuzumab Phase II Median OS 9.6 months 2011 [37]
Table 2. Clinical trials for diffuse intrinsic pontine glioma (DIPG) using targeted therapies
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4. Medulloblastoma
Medulloblastoma, the commonest malignant brain tumor in the pediatric population, is no
longer considered a single disease. Recent efforts of multiple independent groups have
reached to a consensus that medulloblastoma comprises four distinct molecular variants
named WNT, SHH, Group 3 and Group 4 [38]. The subgroups have different demographics,
genetic profiles and prognosis [39]. This may explain why patients with the same histologi‐
cal disease have different clinical outcomes and a variable response to current treatments in‐
cluding surgery, whole-brain radiation and intensive chemotherapy. Figure 1 summarizes
the main features of the four medulloblastoma subgroups.
WNT
(10%)
SHH
(30%)
Group 3
(25%)
Group 4
(35%)
CTNNB1 mutation PTCH1/SMO/SUFU
mutation
MYC amplification
PVT1-MYC fusion
CDK6 amplification
Isochromosome 17q
SNCAIP duplication
Monosomy 6
MYCN amplification
SHH signaling
PI3K signaling
Photoreceptor/GABAergic 
signaling
TGF-ß signaling
Neuronal/Glutamatergic 
signaling
NF-kB signaling
MYC +++ Minimal MYC/MYCN
5y OS 32%
Very frequent M+ Frequent M+
5y OS 76%
MYCN +
5y OS 87%
Uncommon M+
WNT signaling
MYC +
5y OS 94%
Rare M+
Figure 1. Features of the four medulloblastoma subgroups, including molecular genetics and clinical outcome
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4.1. WNT medulloblastomas
WNT medulloblastomas are frequent in older children and teenagers and are rarely seen in
infants. Patients within this subgroup have usually an excellent outcome with survival rates
over 90%. However, Remke et al. showed that this is only true for pediatric cases as adult
WNT patients exhibit survival rates of approximately 80% [40]. Histologically, WNT tumors
are almost always of the classic variant and they rarely disseminate.
This subgroup is enriched in genes of the WNT pathway. Although few gains and losses
were reported in the WNT genome, mutations in CTNNB1 are frequent and usually occur
with deletion of one copy of chromosome 6 (monosomy 6). Patients with CTNNB1 mutation
have accumulation of β-catenin in the nucleus and better survival rates. Positive nuclear im‐
munostaining for β-catenin is now currently accepted as a marker of WNT medulloblasto‐
mas [41,42], although DKK1 and DKK2 were also proposed as markers for this subgroup
[42,43]. The overall good outcome of WNT tumors suggests that this subgroup may be a
good candidate for de-escalation therapy in future clinical trials.
4.2. SHH medulloblastomas
SHH medulloblastomas are frequently found in infants and adults (approximately 60% of
cases in each age group) but are rare in childhood. In the SHH subgroup, prognostic factors
such as M-stage and desmoplasia are age-dependent. Metastasis at presentation represents a
negative prognostic factor only in adults while desmoplasia is associated with worse out‐
come only in pediatric cases [44]. From a histological point of view this subgroup is unique
since it includes tumors of the four main variants (classic, nodular desmoplastic, large-cell
anaplastic and medulloblastoma with extensive nodularity).
SHH medulloblastomas are characterized by aberrant expression of SHH pathway genes in‐
cluding SMO, PTCH1, SUFU and GLI2. Amplifications of MYCN and YAP1 are also seen in
this subgroup. Additionally, deletion of chromosome 9q is a common and highly restricted
event in SHH tumors, most likely secondary to PTCH1 mutation on chromosome 9q22 [45].
Of notice is the fact that the transcriptomes of pediatric and adult SHH tumors have differ‐
ent expression profiles with increased levels of genes related to extracellular matrix function
in the first group and elevated levels of HOX family genes and genes involved in tissue de‐
velopment in the second group [44,46]. In an attempt to simplify the molecular subgrouping
of medulloblastomas, different laboratories used formalin-fixed paraffin-embedded tissues
(FFPE) to test a variety of markers for SHH medulloblastomas including SFRP1, GLI1 and
GAB1 [42,43,47].
The clinical and molecular distinction of infant and adult SHH medulloblastomas suggests a
disparate underlying biology and raises the question of possible different responses to cur‐
rent targeted therapies.
4.3. Group 3 medulloblastomas
Group 3 medulloblastomas are restricted to pediatric patients. Indeed, two recent studies
concluded that Group 3 tumors are extremely rare in adults [40,48]. Another feature of this
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subgroup is its aggressive behavior with high incidence of metastasis, frequent large-cell
anaplastic histology and an invariable dismal prognosis (approximately 20 to 30% overall
survival). It has been shown that Group 3 medulloblastomas consist of two distinct subtypes
one of which harbors frequent amplifications of the MYC gene and has the worse outcome
[49]. Although Group 3 and 4 have some common genetic features, including gain of chro‐
mosome 7, losses of chromosomes 5q and 10q and gain of chromosome 1q are more frequent
in Group 3 tumors. NPR3 and KCNA1 were proposed as biomarkers for Group 3 and Group
4, respectively [42].
Until recently, there were no known targetable pathways in Group 3 medulloblastomas and
the suggested intensification of treatment for these patients would necessarily result in in‐
creased toxicity and morbidity (see below).
4.4. Group 4 medulloblastomas
Group 4 tumors represent simultaneously the most common and the less well-understood
subgroup of medulloblastomas. They are found across all age groups and have an inter‐
mediate prognosis although the adult patients show a reduced survival when compared to
their pediatric counterparts. Group 4 medulloblastomas are usually of the classic variant
and they rarely present with metastasis. The most frequent genetic aberration in Group 4 tu‐
mors, present in up to 80% of cases, is isochromosome 17q (i17q) although MYCN amplifica‐
tions were also reported. The expression of follistatin-related protein 5 (FSTL5) was
identified as a marker of high-risk Group 4 patients [50].
4.5. From genomic revolution to clinical trials in medulloblastoma
Despite important advances in medulloblastoma treatment, approximately 40% of children
will have recurrence and 30% will die from the disease. Moreover, the survivors are often
left with significant disabilities due to cytotoxic side effects of chemotherapy and radiation
to the developing central nervous system (CNS). Identifying the genetic events that drive
medulloblastoma is, therefore, critical to develop more effective and less toxic therapies.
Except for SHH inhibitors that have shown some promise in SHH patients [51], there were
no other targetable genes or pathways for WNT, Group 3 and Group 4 medulloblastomas.
However, very recently published studies from four independent groups dissected the ge‐
nomic landscape of medulloblastoma using large cohorts of patients and the latest high-
throughput technology.
Using SNP arrays in a large cohort of over 1,000 medulloblastoma samples, Northcott et al.
reported that somatic CNAs are a common event in medulloblastoma and are subgroup-
specific [52]. In Group 3 tumors the authors identified recurrent PVT1 gene fusions with
MYC and NDRG1 through chromothripsis, a process of erroneous DNA repair after chromo‐
some shattering. This process of catastrophic DNA rearrangement has been previously
shown in SHH medulloblastomas with TP53 mutations [53]. The most frequent somatic
CNA was a duplication of SNCAIP, a gene on chromosome 5q23.2 involved in Parkinson’s
disease. Interestingly, SNCAIP duplication is restricted to Group 4α, a subtype of Group 4
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with a relatively balanced genome when compared to Group 4β [52]. The authors also re‐
ported novel targetable pathways that could be the basis for future clinical trials, including
PI3K pathway in SHH, TGF-β pathway in Group 3 and NF-κB pathway in Group 4 [52].
Another interesting observation, consistent with the first published study using genome se‐
quencing in medulloblastoma [54], is the low number of somatic mutations found in these
tumors when compared to adult solid tumors and the increased mutation frequency with
age [52,55-57]. Jones et al. also identified tetraploidy as an early event in Group 3 and Group
4 medulloblastomas, concomitant with TP53 mutations in some tumors [55].
The genome sequencing of independent cohorts of medulloblastoma samples and matched
blood, identified previously known mutated genes (CTNNB1, PTCH1, MLL2, SMARCA4,
TP53) but also allowed the discovery of new recurrent somatic mutations (DDX3X,
CTDNEP1, KDM6A, TBR1, GPS2, BCOR, LDB1, EZH2, CHD7, ZMYM3), often subgroup-spe‐
cific [52,55-57]. Notably, these studies identified genes involved in histone modification and
chromatin remodeling complexes across all subgroups, which may explain the complexity
and heterogeneity seen in medulloblastoma.
The ongoing genomic revolution in medulloblastoma is moving the next generation of clini‐
cal trials towards targeted treatments according to the molecular subgroup. SHH inhibitors,
including GDC-0449 and NVP-LDE225, already proved its efficacy in tumor growth reduc‐
tion but the reported acquired resistance suggests that a combination of targeted therapies
may be a key approach to improve response [58]. Phase II clinical trials using GDC-0449 are
now recruiting pediatric and adult patients with recurrent or refractory medulloblastoma
and phase I trials with NVP-LDE225 are recruiting patients with advanced solid tumors in‐
cluding medulloblastoma. Under debate is the de-escalation of therapy in WNT patients and
the intensification of treatment and/or targeted therapy for Group 3 patients [59,60]. Finaly,
the discovery of a significant number of chromatin modifier genes across medulloblastoma
subgroups suggests that histone deacetylase inhibitors may constitute a good therapeutic
option in the future.
5. Ependymoma
Ependymoma, the third most common brain tumor in childhood, is still incurable in up to
45% of patients [61]. The gold standard of treatment is maximal safe surgical resection fol‐
lowed by radiation since chemotherapy is usually ineffective. Ependymomas can arise in
different regions of the CNS including the cerebral hemispheres, the posterior fossa and the
spinal cord. This diversity is extended to its demographic, genetic, clinical and prognostic
characteristics. Both children and adults can be affected although posterior fossa tumors are
more common in children and supratentorial and spinal tumors occur more frequently in
adults. The clinical behavior of ependymoma is variable with some patients experiencing a
fatal clinical course while others have a long recurrence-free survival. The lack of novel tar‐
geted treatments for ependymoma can be explained by the paucity of cell lines and animal
models of the disease.
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The genetic heterogeneity of ependymoma has been highlighted by different studies with
some cohorts of tumors showing frequent chromosomal alterations and others displaying a
balanced genome. Korshunov et al. identified gain of chromosome 1q, CDKN2A homozy‐
gous deletion and age at diagnosis as independent factors of worse prognosis in ependymo‐
ma [62]. Johnson et al. described subgroups of ependymoma clustered by their CNAs,
messenger RNA (mRNA) and microRNA (miRNA) profiles and, interestingly, tumors were
segregated by their CNS location [63]. Furthermore, the authors were able to generate a
mouse model of supratentorial ependymoma presenting strong evidence that the radial glial
cells are likely the cells of origin of this tumor [63]. More recently, Witt et al. transcriptionaly
profiled two large independent cohorts of posterior fossa tumors identifying two distinct
subgroups, Group A and Group B ependymomas [64]. Group A tumors comprise only pos‐
terior fossa ependymomas while Group B tumors include posterior fossa tumors that clus‐
tered with spinal ependymomas. Patients with Group A ependymomas are younger
(median age 2.5 years), with the majority of tumors located laterally and with a balanced ge‐
nome. These patients have higher incidence of recurrence and metastasis and a worse prog‐
nosis (5 year overall survival of 69%). Patients with Group B ependymomas are older
(median age 20 years), with tumors in the midline (95%) and a high degree of genomic insta‐
bility (Figure 2). Although several cytogenetic abnormalities were found in this group, in‐
cluding loss of chromosomes 1, 2, 3, 6, 8, 10, 14q, 17q, 22q, and gain of chromosomes 4, 5q, 7,
9, 11, 12, 15q, 18, 20, and 21q, patients have a good prognosis (5 year overall survival of
95%). The genes that characterize Group B ependymomas are involved in microtubule as‐
sembly and oxidative metabolism while Group A tumors include several pathways associat‐
ed with cancer. The authors identified LAMA2 and NELL2 as markers of Group A and
Group B ependymomas, respectively [64]. Using unsupervised cluster analysis of gene ex‐
pression signatures, others also described two groups of infratentorial ependymomas
(Group 1 and Group 2) that overlap with Group A and Group B of Witt et al., respectively
[65]. The distinct genetic profiles of posterior fossa ependymomas suggest that novel target‐
ed therapies against subgroup-specific pathways maybe the key strategy to improve surviv‐
al, particularly in Group A patients.
The interesting observation that up to 50% of pediatric ependymomas have a balanced ge‐
nome [62] raises the possibility that epigenetic mechanisms may play a role in ependymoma
pathogenesis. Most studies have focused on promoter hypermethylation of candidate genes
known to be tumor suppressor genes in ependymoma or frequently methylated in other
cancers. HIC-1 and RASSF1A promoter hypermethylation were described in 83% and 86% of
ependymomas, respectively. They are known to be tumor suppressor genes, silenced by hy‐
permethylation in many human cancers [66]. Promoter hypermethylation of other genes, in‐
cluding CDKN2A (21%), CDKN2B (32%), p14ARF (21%), and MGMT (27%) were also
reported in studies with large cohorts of tumor samples [66]. More recently, Rogers et al.
used an array-based analysis to determine the methylation profile of 98 ependymomas [67].
The authors found that supratentorial and spinal ependymomas have a hypermethylated
phenotype and that the genes identified are involved in cell growth and apoptosis. The in‐
crease in promoter methylation of CpG islands across a large number of genes has been de‐
scribed in other cancers as CpG island methylator phenotype (CIMP). Although it has been
New Molecular Targets and Treatments for Pediatric Brain Tumors
http://dx.doi.org/10.5772/53300
565
correlated to a worse outcome in other cancers, the authors could not find an association be‐
tween methylation and prognosis in ependymomas [67].
Figure 2. Features of the posterior fossa ependymoma subgroups, including genetic profile, clinical features and
prognosis.
Another less frequent epigenetic event in cancer genomes is hypomethylation. This loss of
DNA methylation occurs mainly in repetitive elements (Alu repeats). In a recent study, Xie
et al. used a genome-wide approach to study the methylation profiles of Alu repeat sequen‐
ces in pediatric intracranial ependymomas [68]. Notably, they identified a global loss of
methylation in the regions flanking, rather than within, Alu sequences, and this was corre‐
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lated with a more agressive tumor phenotype. The biological significance of this finding is
yet to be unraveled.
The increased knowledge of the genetic and epigenetic events that drive ependymoma may
lead to more effective targeted therapies aimed to repair molecular functions and dysregu‐
lated pathways. However, there are currently no clinical trials evaluating specific molecular
therapies in ependymoma. Despite the recent achievements in ependymoma research, great‐
er progress is needed to decifer the molecular and biological mechanisms of this disease
and, ultimately, to improve patient’s clinical outcome.
6. Conclusion
Major steps have been made to a better understanding of the molecular genetics underlying
the most common pediatric brain tumors. An important advance was to recognize that adult
and pediatric brain tumors are distinct and, therefore, need different therapeutic ap‐
proaches. This knowledge opened new avenues for targeted therapies and clinical trials
based on tumor-specific molecular subgrouping are currently ongoing. When compared to
standard chemotherapy and radiation, the use of biological agents has several advantages.
They can target cancer cells and spare normal cells in the developing CNS of children and
also be used to delay radiotherapy, which is responsible for long-term side effects of treat‐
ment. Many of the newer agents are small molecules, with low molecular weight, which fa‐
cilitates blood-brain barrier penetration. However, despite the enthusiasm with the phase I
and phase II clinical trials using biological agents as monotherapy, mainly for progressive
and recurrent brain tumors, efficacy has not yet been proven. In the future, combination
therapies will likely be needed to target multiple pathways involved in tumorigenesis and
to overcome the cytostatic effect of several biological agents. As the amount of data generat‐
ed by high-throughput studies increases the drugable targets for each pediatric brain tumor,
the number of clinical trials will continue to expand aiming a better control of the disease
with less morbidity and extended survival.
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